Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

TEVA reports decent third-quarter results. The company raises its revenue guidance for 2023 for the second time this year while keeping the EPS range intact.

TEVA Q3 Earnings In Line, Sales Beat, Revenue View Raised

Teva Pharmaceutical Industries (NYSE:TEVA ) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Ran Meir - Senior Vice President, Investor Relations Richard Francis - President and Chief Executive Officer, Member of the Board of Directors Eric Hughes - Executive Vice President, Global R&D and Chief Medical Officer Eli Kalif - Executive Vice President, Chief Financial Officer Sven Dethlefs - Executive Vice President, North America Commercial Conference Call Participants Umer Raffat - Evercore ISI Balaji Prasad - Barclays Jason Gerberry - Bank of America Merrill Lynch Nathan Rich - Goldman Sachs Glen Santangelo - Jefferies David Amsellem - Piper Sandler Operator Hello, and welcome to the Q3 2023 Teva Pharmaceutical Industries Limited Earnings Conference Call. My name is Alex.

Teva Pharmaceutical Industries (TEVA) Q3 2023 Earnings Call Transcript

Teva Pharmaceutical Industries (NASDAQ:TEVA), one of Israel's largest companies and a global leader in generic medicine production, said Wednesday that it has raised its revenue guidance for the second consecutive quarter, attributing the boost to its relatively unaffected medicine production amid the recent month-long conflict in Israel. Teva's CEO, Richard Francis, expressed gratitude that the company's production facilities had remained "largely unaffected" despite the war that began on October 7.

Teva Pharmaceuticals says production is largely unaffected from Israel-Hamas conflict, raises guidance

While the top- and bottom-line numbers for Teva Pharmaceutical Industries Ltd. (TEVA) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Teva Pharmaceutical Industries Ltd. (TEVA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Teva topped third-quarter forecasts on Wednesday and raised its outlook for the year. Teva stock jumped in premarket trading.

Teva Closes In On A Buy Point On Third-Quarter Beat, Business Separation

Teva Pharmaceutical Industries Ltd.'s American depositary receipts TEVA, -0.11% gained 3% premarket on Wednesday after the company reported third-quarter sales that topped expectations and raised its full-year revenue guidance.

Teva shares climb as third-quarter sales top estimates

Teva Pharmaceutical Industries reported slightly higher third-quarter profit, helped by sales of its Austedo treatment for Huntington's Disease, and said production in Israel was unaffected by the country's war with Hamas in Gaza.

Teva Pharm Q3 profit rises, sees higher 2023 revenue

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2023. Mr. Richard Francis, Teva's President and CEO, commenting on the war in Israel, said: "Following the terror attacks in Israel on October 7, 2023, Teva's Board, leadership team, and I have made the safety of our Israeli employees our utmost priority. As a company with deep roots in Israel, we are humbled by the incredible resilience, care a.

Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active Pharmaceutical Ingredients business (Teva api). Dr. Ananth will lead the API business starting November 27, 2023, and will be based out of Teva's U.S. headquarters in Parsippany, NJ. Richard Francis, Teva's President and CEO said: “I am excited to welcome Ananth back to Teva to lead the Teva api business during.

Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new HD data will be presented at the Huntington Study Group® (HSG) Annual Meeting on November 2-4 in Phoenix, AZ. “Through our discussions with the HD community, we understand the importance of providing treatment options that are not only safe and effective but set patients up for success by ensuring treatment regimens are ma.

Teva to Present New Data Supporting Safety, Efficacy and Real-World Effectiveness of AUSTEDO® (deutetrabenazine) Tablets at the 2023 HSG Annual Meeting

SANTA BARBARA, Calif. & PARSIPPANY, N.J.--(BUSINESS WIRE)--Direct Relief, the National Association of Free and Charitable Clinics (NAFC), and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the continued funding of 11 local free and charitable clinics in the U.S. as part of a $2 million, two-year commitment, through their collaborative Community Routes: Access to Mental Health Care program that aims to advance access to health.

Teva to Provide Second Round of Funding to Clinics in California, Florida and New Jersey as Part of $2 Million Commitment Through Community Routes: Access to Mental Health Care Program

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announce that data from the UNITE study presented today at the World Congress of Neurology in Montreal, Canada, show that AJOVY® (fremanezumab) reduced migraine attacks and depression symptoms in migraine patients with major depressive disorder. AJOVY® is currently approved for the preventive treatment of migraine in adults. Depression is one of the most prevalent psychiatric co-morbidities in migraine.

Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder

AMSTERDAM--(BUSINESS WIRE)--Leading supply chain visibility provider FourKites today announced that Teva, a global leader in generic and innovative medicines, has achieved a 0.005% incident rate by leveraging FourKites' global carrier visibility solution, NIC-Place. With NIC-Place, Teva has instant access to and can react to high-quality temperature and theft data, which saves time and avoids loss of goods. Teva has a portfolio consisting of more than 3,500 products in nearly every therapeutic.

Teva Leverages Market-leading Temperature and Theft Tracking from FourKites to Deliver Critical Medicines Around the World

AMSTERDAM--(BUSINESS WIRE)--FourKites today announces that Teva, a global leader in generic and innovative medicines has achieved a 0.005% incident rate by leveraging FourKites' global carrier visibility solution, NIC-Place. With NIC-Place, Teva has instant access to and can react to high-quality temperature and theft data, which saves time and avoids loss of goods. Teva has a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the worl.

Teva Leverages Market-leading Temperature & Theft Tracking from FourKites to Deliver Critical Medicines Around the World

Israel's war with Hamas is not expected to have much impact on Teva Pharmaceutical Industries' business performance, the company said on Tuesday.

Drugmaker Teva does not see big impact on business from Israel-Hamas war

Elbit Systems

Fiverr

Hub Cyber Security Ltd

Mobileye Global Inc

monday.com

TAT Technologies

Two days ago, the Palestinian militant group Hamas launched a full-scale attack on Israel from the Gaza Strip. Since then, a full-scale conflict has escalated with many civilian casualties.

Israeli Stocks Fall as Investors Fear Middle East Conflict

Compugen

Gamida Cell Ltd

Kamada

Protalix Biotherapeutics

Taro Pharmaceutical Industries

Shares of Israeli pharmaceutical companies took a hit in premarket trades Monday after Hamas' attack on Israel.

These Israeli pharmaceutical stocks are down in the wake of Hamas attack

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2023 financial results on Wednesday, November 8, 2023, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available.

Teva to Host Conference Call to Discuss Third Quarter 2023 Financial Results at 8 a.m. ET on November 8, 2023

Sanofi

Teva stock tumbled Wednesday after the company announced it would partner with Sanofi to develop an inflammatory bowel disease treatment.

Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble.

Teva Pharmaceutical Industries Ltd.'s TEVA, -4.10% new collaboration with Sanofi SNY, on an inflammatory bowel disease treatment “will pay dividends” from a commercial perspective, Evercore ISI analysts wrote in a note Wednesday, as the companies team up on a therapy that's drawing growing investor interest.

Teva partnership with Sanofi ‘will pay dividends,' analyst says

Teva Pharmaceutical Industries said on Wednesday it will collaborate with French drugmaker Sanofi to co-develop its treatment for ulcerative colitis and Crohn's disease that it expects to ultimately be a blockbuster drug.

Sanofi to co-develop Teva Pharmaceutical's Colitis, Crohn's drug

PARIS & PARSIPPANY, N.J--(BUSINESS WIRE)--Sanofi (EURONEXT: SAN and NASDAQ: SNY) and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announce today a collaboration to co-develop and co-commercialize asset TEV ‘574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, two types of inflammatory bowel disease. Paul Hudson Chief Executive Officer, Sanofi “Anti-TL1As are a promising class of therapies,.

Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment

Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment

Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment

Press Release - Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced changes to its leadership team. Sven Dethlefs, Executive Vice President, North America Commercial, will leave Teva on November 17, 2023, and Christine (Chris) Fox, who most recently served as Global President, Gene Therapies at Novartis will be the new head of Teva's U.S. Commercial Business. “On behalf of the Teva Board of Directors and our executive management team,.

News for Teva Pharmaceutical Stock (TEVA)